Vedolizumab in Mild-to-Moderate Crohn's Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study.

Background: In real-world experience, the number of patients using vedolizumab as first-line biological therapy was low. We aimed to evaluate the effectiveness and safety of vedolizumab in mild-to-moderate Crohn's disease (CD) biologic-naïve patients. Methods: We performed a retrospective multicentric cohort study with patients who had clinical activity scores (Harvey-Bradshaw Index [HBI]) measured at baseline and weeks 12, 26, 52, as well as at the last follow-up. Clinical response was defined as a reduction ≥3 in HBI, whereas clinical remission as HBI ≤4. Mucosal healing was defined as the complete absence of ulcers in control colonoscopies. Kaplan-Meier survival analysis was used to assess the persistence with vedolizumab. Results: From a total of 66 patients, 53% (35/66) reached clinical remission at week 12. This percentage increased to 69.7% (46/66) at week 26, and 78.8% (52/66) at week 52. Mucosal healing was achieved in 62.3% (33/53) of patients. Vedolizumab was well tolerated, and most adverse events were minor. During vedolizumab treatment, 3/66 patients underwent surgery. Conclusions: This study demonstrates the effectiveness and safety of vedolizumab as a first-line biological agent in patients with mild-to-moderate CD.

Prevalence of anal intraepithelial lesions in patients with inflammatory bowel disease

Introduction: Anal intraepithelial neoplasia (AIN) is a premalignant lesion of the anal canal associated with HPV, with a higher prevalence in immunosuppressed individuals. Patients with inflammatory bowel disease (IBD) are at potential risk for their development, due to the use of immunosuppressants and certain characteristics of the disease. Method: This is a prospective, cross-sectional, and interventional study that included 53 patients with IBD treated at a tertiary outpatient clinic, who underwent anal smear for cytology in order to assess the prevalence of AIN and associated risk factors. Results: Forty-eight samples were negative for dysplasia and 2 were positive (4%). Both positive samples occurred in women, with Crohn's disease (CD), who were immunosuppressed and had a history of receptive anal intercourse. Discussion: The prevalence of anal dysplasia in IBD patients in this study is similar to that described in low-risk populations. Literature data are scarce and conflicting and there is no evidence to recommend screening with routine anal cytology in patients with IBD. Female gender, history of receptive anal intercourse, immunosuppression and CD seem to be risk factors. (AU)

História familial e câncer colorretal em idade precoce: deve-se indicar colectomia estendida? / Family history of colorectal cancer at early age: should extended colectomy be indicated?

OBJETIVO: avaliar a história familial e as características dos tumores em dois grupos distintos por sua faixa etária, bem como questionar quanto à necessidade de colectomia estendida, baseando-se nestas características. MÉTODO: Em estudo retrospectivo analisaram-se 106 pacientes por meio do prontuário e de contato telefônico com o próprio doente e/ou familiares, operados no HC-UFPR. Foram divididos em 2 grupos: Grupo A (n=51) com 55 anos ou menos, e Grupo B (n=55) com mais de 55 anos. Avaliou-se o número de doentes com parentes de 1º. grau com câncer colorretal e em outros sítios; o número de parentes com CCR; o sítio do tumor; o estadiamento TNM; os óbitos no período e a presença de neoplasias associadas. RESULTADOS: No grupo A, 16 (31,4 por cento) pacientes tinham parentes com câncer colorretal. No grupo B, sete (12,7 por cento) (p=0,032). No grupo A houve 16 (31,4 por cento) pacientes de familiares com outro tipo de neoplasia. No grupo B, 19 (34,5 por cento) doentes (p=0,837). Ao incluírem-se apenas as neoplasias associadas à Síndrome do HNPCC, como endométrio e estômago, houve 5 (9,8 por cento) pacientes no grupo A e 3 (5,9 por cento) no grupo B (p=0,477). No grupo A, 3 (5,8 por cento) doentes apresentaram neoplasias associadas ao CCR, sendo elas estômago, rim e bexiga. No grupo B, 3 (5,4 por cento) doentes, mas os tumores eram de mama e próstata (p=0,624). Predominou no grupo A pacientes com estádio III (41,2 por cento) e no grupo B, o estádio II (51,9 por cento) (p=0,480). Houve 19,6 por cento de óbitos no grupo A e 32,7 por cento no Grupo B (p=0,185). CONCLUSÃO: Pacientes com idade = 55 anos possuem história familial mais representativa para o CCR que pacientes mais idosos, podendo fazer parte da síndrome do HNPCC. Possivelmente se beneficiem de colectomia estendida.

AIM: To evaluate the family history and the characteristics of the tumors in two different groups of patients, divided by age, questioning the necessity of extensive colectomy for the adequate treatment. METHODS: One hundred and six patients were analyzed retrospectively by hospital chart review or phone contact either with the patient or a next of keen; all were operated at the University Hospital of the "Universidade Federal do Paraná" (Brazil).These patients were divided in Group A (n=51) below 55 years old, and Group B (n=55) with age above 55 years. All patients were analyzed for first degree relatives with history of colon and rectal cancer and cancer history in other organs; number of relatives with colon and rectal cancer; the location of the tumors in the colon; the TNM staging; the occurrence of other malignant neoplasias for each patient; and the death rate for the period of the study. RESULTS: On group A, 16 (31.4 percent) patients had relatives with colorectal cancer; on group B, 7 (12.7 percent) (p=0,032). On group A, 16 (31.4 percent) patients had relatives with other types of malignant neoplasias, and on group B, 19 (34.5 percent) (p=0.837). When it was considered only cancers related to the HNPCC syndrome, as endometrium and stomach, 5 (9.8 percent) patients were found on group A and 3 (5.9 percent) on group B (p=0.477). On group A, 3 (5.8 percent) patients had tumors related to colon and rectal cancers, as stomach, kidney and bladder. On group B, 3 (5.4 percent) patients, but these tumors were in the breast and prostate (p=0.624). On group A, there were more patients with stage III cancers (41.2 percent) and on group B, stage II cancers were more prevalent (51.9 percent) (p=0.480). The death rate was 19.6 percent on group A and 32.7 percent on group B (p=0.185). CONCLUSION: Patients under 55 years of age have an increased family history of colon and rectal cancer when compared to the ones above the age of 55; those could be related to the HNPCC...